Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients…
- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with…
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its continued…
BOSTON and SHANGHAI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics…
FDA-approved non-invasive treatment for depression and OCD now available at Contemporary Care’s Naples clinicImage by Contemporary Care NAPLES, Fla., Oct.…
Geniant Cranial offers precision, compact footprint, and flexible patient positioning for hospitals seeking to enhance neurosurgical outcomes SAN DIEGO, Oct.…
The Company expects to reestablish and announce a new record date as soon as possibleALAMEDA, Calif., Oct. 03, 2025 (GLOBE…
Small Business Innovation Research Grant will advance a novel neuroplastogen towards IND as potential treatment for Alcohol Use Disorder (AUD).…
Strategic integration fuels Asabys' goal to build a beyond €1 billion life sciences investment platform in Europe by 2030 Asabys incorporates…
This groundbreaking program harnesses neuroplasticity by combining the clinical strengths of counseling with the brain-enhancing power of exercise, offering a…